Cancer Research SABCS Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Butler, L. M.
Right arrow Articles by Richon, V. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Butler, L. M.
Right arrow Articles by Richon, V. M.
[Cancer Research 60, 5165-5170, September 15, 2000]
© 2000 American Association for Cancer Research

Experimental Therapeutics

Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Suppresses the Growth of Prostate Cancer Cells in Vitro and in Vivo1

Lisa M. Butler, David B. Agus, Howard I. Scher, Brian Higgins, Adam Rose, Carlos Cordon-Cardo, Howard T. Thaler, Richard A. Rifkind, Paul A. Marks and Victoria M. Richon2

Cell Biology Program [L. M. B., A. R., R. A. R., P. A. M., V. M. R.], Laboratory of Tumor Biology [D. B. A., B. H.], Genitourinary Oncology Service [H. I. S.], Department of Pathology [C. C-C.], and Department of Epidemiology and Biostatistics Service [H. T. T.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021

Suberoylanilide hydroxamic acid (SAHA) is the prototype of a family of hybrid polar compounds that induce growth arrest in transformed cells and show promise for the treatment of cancer. SAHA induces differentiation and/or apoptosis in certain transformed cells in culture and is a potent inhibitor of histone deacetylases. In this study, we examined the effects of SAHA on the growth of human prostate cancer cells in culture and on the growth of the CWR22 human prostate xenograft in nude mice. SAHA suppressed the growth of the LNCaP, PC-3, and TSU-Pr1 cell lines at micromolar concentrations (2.5–7.5 µM). SAHA induced dose-dependent cell death in the LNCaP cells. In mice with transplanted CWR22 human prostate tumors, SAHA (25, 50, and 100 mg/kg/day) caused significant suppression of tumor growth compared with mice receiving vehicle alone; treatment with 50 mg/kg/day resulted in a 97% reduction in the mean final tumor volume compared with controls. At this dose, there was no detectable toxicity as evaluated by weight gain and necropsy examination. Increased accumulation of acetylated core histones was detected in the CWR22 tumors within 6 h of SAHA administration. SAHA induced prostate-specific antigen mRNA expression in CWR22 prostate cancer cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. The results suggest that hydroxamic acid-based hybrid polar compounds inhibit prostate cancer cell growth and may be useful, relatively nontoxic agents for the treatment of prostate carcinoma.




This article has been cited by other articles:


Home page
 J. Nutr.Home page
E. Ho, J. D. Clarke, and R. H. Dashwood
Dietary Sulforaphane, a Histone Deacetylase Inhibitor for Cancer Prevention
J. Nutr., December 1, 2009; 139(12): 2393 - 2396.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Arts, P. King, A. Marien, W. Floren, A. Belien, L. Janssen, I. Pilatte, B. Roux, L. Decrane, R. Gilissen, et al.
JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity
Clin. Cancer Res., November 15, 2009; 15(22): 6841 - 6851.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
E. W. Schaefer, A. Loaiza-Bonilla, M. Juckett, J. F. DiPersio, V. Roy, J. Slack, W. Wu, K. Laumann, I. Espinoza-Delgado, S. D. Gore, et al.
A phase 2 study of vorinostat in acute myeloid leukemia
Haematologica, October 1, 2009; 94(10): 1375 - 1382.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. S. Welsbie, J. Xu, Y. Chen, L. Borsu, H. I. Scher, N. Rosen, and C. L. Sawyers
Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate Cancer
Cancer Res., February 1, 2009; 69(3): 958 - 966.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. J. Chou, D. Herman, and J. M. Gottesfeld
Pimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases
J. Biol. Chem., December 19, 2008; 283(51): 35402 - 35409.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
P. Gallo, M. V.G. Latronico, P. Gallo, S. Grimaldi, F. Borgia, M. Todaro, P. Jones, P. Gallinari, R. De Francesco, G. Ciliberto, et al.
Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure
Cardiovasc Res, December 1, 2008; 80(3): 416 - 424.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
M. S. Makki, T. Heinzel, and C. Englert
TSA downregulates Wilms tumor gene 1 (Wt1) expression at multiple levels
Nucleic Acids Res., July 1, 2008; 36(12): 4067 - 4078.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Miyanaga, A. Gemma, R. Noro, K. Kataoka, K. Matsuda, M. Nara, T. Okano, M. Seike, A. Yoshimura, A. Kawakami, et al.
Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
Mol. Cancer Ther., July 1, 2008; 7(7): 1923 - 1930.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
R Glauben, A Batra, T Stroh, U Erben, I Fedke, H A Lehr, F Leoni, P Mascagni, C A Dinarello, M Zeitz, et al.
Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice
Gut, May 1, 2008; 57(5): 613 - 622.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. A. Hassig, K. T. Symons, X. Guo, P.-M. Nguyen, T. Annable, P. L. Wash, J. E. Payne, D. A. Jenkins, C. Bonnefous, C. Trotter, et al.
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo
Mol. Cancer Ther., May 1, 2008; 7(5): 1054 - 1065.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Fournel, C. Bonfils, Y. Hou, P. T. Yan, M.-C. Trachy-Bourget, A. Kalita, J. Liu, A.-H. Lu, N. Z. Zhou, M.-F. Robert, et al.
MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
Mol. Cancer Ther., April 1, 2008; 7(4): 759 - 768.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Fan, J. Stanfield, Y. Guo, J. A. Karam, E. Frenkel, X. Sun, and J.-T. Hsieh
Effect of Trans-2,3-Dimethoxycinnamoyl Azide on Enhancing Antitumor Activity of Romidepsin on Human Bladder Cancer
Clin. Cancer Res., February 15, 2008; 14(4): 1200 - 1207.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. R. Fantin and V. M. Richon
Mechanisms of Resistance to Histone Deacetylase Inhibitors and Their Therapeutic Implications
Clin. Cancer Res., December 15, 2007; 13(24): 7237 - 7242.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. M. Gillenwater, M. Zhong, and R. Lotan
Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells
Mol. Cancer Ther., November 1, 2007; 6(11): 2967 - 2975.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
K. Ishihama, M. Yamakawa, S. Semba, H. Takeda, S. Kawata, S. Kimura, and W. Kimura
Expression of HDAC1 and CBP/p300 in human colorectal carcinomas
J. Clin. Pathol., November 1, 2007; 60(11): 1205 - 1210.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
T.-M. Lee, M.-S. Lin, and N.-C. Chang
Inhibition of histone deacetylase on ventricular remodeling in infarcted rats
Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H968 - H977.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. A. Olsen, Y. H. Kim, T. M. Kuzel, T. R. Pacheco, F. M. Foss, S. Parker, S. R. Frankel, C. Chen, J. L. Ricker, J. M. Arduino, et al.
Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma
J. Clin. Oncol., July 20, 2007; 25(21): 3109 - 3115.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Sharma, C. E.S. Comstock, E. S. Knudsen, K. H. Cao, J. K. Hess-Wilson, L. M. Morey, J. Barrera, and K. E. Knudsen
Retinoblastoma Tumor Suppressor Status Is a Critical Determinant of Therapeutic Response in Prostate Cancer Cells
Cancer Res., July 1, 2007; 67(13): 6192 - 6203.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
F. Alimirah, J. Chen, F. J. Davis, and D. Choubey
IFI16 in Human Prostate Cancer
Mol. Cancer Res., March 1, 2007; 5(3): 251 - 259.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Vlasakova, Z. Novakova, L. Rossmeislova, M. Kahle, P. Hozak, and Z. Hodny
Histone deacetylase inhibitors suppress IFN{alpha}-induced up-regulation of promyelocytic leukemia protein
Blood, February 15, 2007; 109(4): 1373 - 1380.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
M. C. Myzak, P. Tong, W.-M. Dashwood, R. H. Dashwood, and E. Ho
Sulforaphane Retards the Growth of Human PC-3 Xenografts and Inhibits HDAC Activity in Human Subjects
Experimental Biology and Medicine, February 1, 2007; 232(2): 227 - 234.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Yin, J. M. Ong, J. Hu, J. C. Desmond, N. Kawamata, B. M. Konda, K. L. Black, and H. P. Koeffler
Suberoylanilide Hydroxamic Acid, a Histone Deacetylase Inhibitor: Effects on Gene Expression and Growth of Glioma Cells In vitro and In vivo
Clin. Cancer Res., February 1, 2007; 13(3): 1045 - 1052.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. B. Arnold, N. Arkus, J. Gunn, and M. Korc
The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Induces Growth Inhibition and Enhances Gemcitabine-Induced Cell Death in Pancreatic Cancer
Clin. Cancer Res., January 1, 2007; 13(1): 18 - 26.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. L. Marrocco, W. D. Tilley, T. Bianco-Miotto, A. Evdokiou, H. I. Scher, R. A. Rifkind, P. A. Marks, V. M. Richon, and L. M. Butler
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation
Mol. Cancer Ther., January 1, 2007; 6(1): 51 - 60.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Duvic, R. Talpur, X. Ni, C. Zhang, P. Hazarika, C. Kelly, J. H. Chiao, J. F. Reilly, J. L. Ricker, V. M. Richon, et al.
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
Blood, January 1, 2007; 109(1): 31 - 39.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
G. Faraco, T. Pancani, L. Formentini, P. Mascagni, G. Fossati, F. Leoni, F. Moroni, and A. Chiarugi
Pharmacological Inhibition of Histone Deacetylases by Suberoylanilide Hydroxamic Acid Specifically Alters Gene Expression and Reduces Ischemic Injury in the Mouse Brain
Mol. Pharmacol., December 1, 2006; 70(6): 1876 - 1884.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
W. Xu, L. Ngo, G. Perez, M. Dokmanovic, and P. A. Marks
Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor
PNAS, October 17, 2006; 103(42): 15540 - 15545.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Huang and B. Guo
Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells.
Cancer Res., September 15, 2006; 66(18): 9245 - 9251.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. K. Kulp, C.-S. Chen, D.-S. Wang, C.-Y. Chen, and C.-S. Chen
Antitumor Effects of a Novel Phenylbutyrate-Based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer
Clin. Cancer Res., September 1, 2006; 12(17): 5199 - 5206.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Munshi, T. Tanaka, M. L. Hobbs, S. L. Tucker, V. M. Richon, and R. E. Meyn
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of {gamma}-H2AX foci.
Mol. Cancer Ther., August 1, 2006; 5(8): 1967 - 1974.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Q. Xia, J. Sung, W. Chowdhury, C.-l. Chen, N. Hoti, S. Shabbeer, M. Carducci, and R. Rodriguez
Chronic Administration of Valproic Acid Inhibits Prostate Cancer Cell Growth In vitro and In vivo.
Cancer Res., July 15, 2006; 66(14): 7237 - 7244.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
I. Y. Eyupoglu, E. Hahnen, C. Trankle, N. E. Savaskan, F. A. Siebzehnrubl, R. Buslei, D. Lemke, W. Wick, R. Fahlbusch, and I. Blumcke
Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275
Mol. Cancer Ther., May 1, 2006; 5(5): 1248 - 1255.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. J. Buggy, Z. A. Cao, K. E. Bass, E. Verner, S. Balasubramanian, L. Liu, B. E. Schultz, P. R. Young, and S. A. Dalrymple
CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo
Mol. Cancer Ther., May 1, 2006; 5(5): 1309 - 1317.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Sankaranarayanapillai, W. P. Tong, D. S. Maxwell, A. Pal, J. Pang, W. G. Bornmann, J. G. Gelovani, and S. M. Ronen
Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy
Mol. Cancer Ther., May 1, 2006; 5(5): 1325 - 1334.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. Glauben, A. Batra, I. Fedke, M. Zeitz, H. A. Lehr, F. Leoni, P. Mascagni, G. Fantuzzi, C. A. Dinarello, and B. Siegmund
Histone hyperacetylation is associated with amelioration of experimental colitis in mice.
J. Immunol., April 15, 2006; 176(8): 5015 - 5022.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. C. Myzak, K. Hardin, R. Wang, R. H. Dashwood, and E. Ho
Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells
Carcinogenesis, April 1, 2006; 27(4): 811 - 819.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. J. Pienta and D. Bradley
Mechanisms underlying the development of androgen-independent prostate cancer.
Clin. Cancer Res., March 15, 2006; 12(6): 1665 - 1671.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Takada, A. Gillenwater, H. Ichikawa, and B. B. Aggarwal
Suberoylanilide Hydroxamic Acid Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis by Suppressing Nuclear Factor-{kappa}B Activation
J. Biol. Chem., March 3, 2006; 281(9): 5612 - 5622.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
N. K. Mukhopadhyay, E. Weisberg, D. Gilchrist, R. Bueno, D. J. Sugarbaker, and M. T. Jaklitsch
Effectiveness of Trichostatin A as a Potential Candidate for Anticancer Therapy in Non-Small-Cell Lung Cancer
Ann. Thorac. Surg., March 1, 2006; 81(3): 1034 - 1042.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
O. W. Rokhlin, R. B. Glover, N. V. Guseva, A. F. Taghiyev, K. G. Kohlgraf, and M. B. Cohen
Mechanisms of Cell Death Induced by Histone Deacetylase Inhibitors in Androgen Receptor-Positive Prostate Cancer Cells
Mol. Cancer Res., February 1, 2006; 4(2): 113 - 123.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. A. O'Connor, M. L. Heaney, L. Schwartz, S. Richardson, R. Willim, B. MacGregor-Cortelli, T. Curly, C. Moskowitz, C. Portlock, S. Horwitz, et al.
Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies
J. Clin. Oncol., January 1, 2006; 24(1): 166 - 173.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Entin-Meer, A. Rephaeli, X. Yang, A. Nudelman, S. R. VandenBerg, and D. A. Haas-Kogan
Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas
Mol. Cancer Ther., December 1, 2005; 4(12): 1952 - 1961.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. D. Loberg, C. J. Logothetis, E. T. Keller, and K. J. Pienta
Pathogenesis and Treatment of Prostate Cancer Bone Metastases: Targeting the Lethal Phenotype
J. Clin. Oncol., November 10, 2005; 23(32): 8232 - 8241.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. I. Scher and C. L. Sawyers
Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis
J. Clin. Oncol., November 10, 2005; 23(32): 8253 - 8261.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Ogawa, T. Hayashi, M. Tokunou, K. Nakachi, J. E. Trosko, C.-C. Chang, and N. Yorioka
Suberoylanilide Hydroxamic Acid Enhances Gap Junctional Intercellular Communication via Acetylation of Histone Containing Connexin 43 Gene Locus
Cancer Res., November 1, 2005; 65(21): 9771 - 9778.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. R. Acharya, A. Sparreboom, J. Venitz, and W. D. Figg
Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review
Mol. Pharmacol., October 1, 2005; 68(4): 917 - 932.
[Abstract] [Full Text] [PDF]

Home page
 Phil Trans R Soc BHome page
B. R Blazar and W. J Murphy
Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD)
Phil Trans R Soc B, September 29, 2005; 360(1461): 1747 - 1767.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
K. J. Pienta and D. C. Smith
Advances in Prostate Cancer Chemotherapy: A New Era Begins
CA Cancer J Clin, September 1, 2005; 55(5): 300 - 318.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W.-S. Xu, G. Perez, L. Ngo, C.-Y. Gui, and P. A. Marks
Induction of Polyploidy by Histone Deacetylase Inhibitor: A Pathway for Antitumor Effects
Cancer Res., September 1, 2005; 65(17): 7832 - 7839.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Chen, S. Meng, H. Wang, P. Bali, W. Bai, B. Li, P. Atadja, K. N. Bhalla, and J. Wu
Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824
Mol. Cancer Ther., September 1, 2005; 4(9): 1311 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. S. Mitsiades, V. Poulaki, C. McMullan, J. Negri, G. Fanourakis, A. Goudopoulou, V. M. Richon, P. A. Marks, and N. Mitsiades
Novel Histone Deacetylase Inhibitors in the Treatment of Thyroid Cancer
Clin. Cancer Res., May 15, 2005; 11(10): 3958 - 3965.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. C. Drummond, C. Marx, Z. Guo, G. Scott, C. Noble, D. Wang, M. Pallavicini, D. B. Kirpotin, and C. C. Benz
Enhanced Pharmacodynamic and Antitumor Properties of a Histone Deacetylase Inhibitor Encapsulated in Liposomes or ErbB2-Targeted Immunoliposomes
Clin. Cancer Res., May 1, 2005; 11(9): 3392 - 3401.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
L.-C. Li, P. R. Carroll, and R. Dahiya
Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment
J Natl Cancer Inst, January 19, 2005; 97(2): 103 - 115.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. S. Ungerstedt, Y. Sowa, W.-S. Xu, Y. Shao, M. Dokmanovic, G. Perez, L. Ngo, A. Holmgren, X. Jiang, and P. A. Marks
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors
PNAS, January 18, 2005; 102(3): 673 - 678.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. C. Hsi, X. Xi, R. Lotan, I. Shureiqi, and S. M. Lippman
The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Induces Apoptosis via Induction of 15-Lipoxygenase-1 in Colorectal Cancer Cells
Cancer Res., December 1, 2004; 64(23): 8778 - 8781.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. M. Reilly, N. Mishra, J. M. Miller, D. Joshi, P. Ruiz, V. M. Richon, P. A. Marks, and G. S. Gilkeson
Modulation of Renal Disease in MRL/lpr Mice by Suberoylanilide Hydroxamic Acid
J. Immunol., September 15, 2004; 173(6): 4171 - 4178.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
H. I Scher, G. Buchanan, W. Gerald, L. M Butler, and W. D Tilley
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer
Endocr. Relat. Cancer, September 1, 2004; 11(3): 459 - 476.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C.-Y. Gui, L. Ngo, W. S. Xu, V. M. Richon, and P. A. Marks
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1
PNAS, February 3, 2004; 101(5): 1241 - 1246.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. S. Mitsiades, N. S. Mitsiades, C. J. McMullan, V. Poulaki, R. Shringarpure, T. Hideshima, M. Akiyama, D. Chauhan, N. Munshi, X. Gu, et al.
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications
PNAS, January 13, 2004; 101(2): 540 - 545.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. R. Brody, S. S. Kadkol, M. C. Hauer, F. Rajaii, J. Lee, and G. R. Pasternack
pp32 Reduction Induces Differentiation of TSU-Pr1 Cells
Am. J. Pathol., January 1, 2004; 164(1): 273 - 283.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. C. Kutko, R. D. Glick, L. M. Butler, D. C. Coffey, R. A. Rifkind, P. A. Marks, V. M. Richon, and M. P. LaQuaglia
Histone Deacetylase Inhibitors Induce Growth Suppression and Cell Death in Human Rhabdomyosarcoma in Vitro
Clin. Cancer Res., November 15, 2003; 9(15): 5749 - 5755.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
R. J. Ferrante, J. K. Kubilus, J. Lee, H. Ryu, A. Beesen, B. Zucker, K. Smith, N. W. Kowall, R. R. Ratan, R. Luthi-Carter, et al.
Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice
J. Neurosci., October 15, 2003; 23(28): 9418 - 9427.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Di Padova, T. Bruno, F. De Nicola, S. Iezzi, C. D'Angelo, R. Gallo, D. Nicosia, N. Corbi, A. Biroccio, A. Floridi, et al.
Che-1 Arrests Human Colon Carcinoma Cell Proliferation by Displacing HDAC1 from the p21WAF1/CIP1 Promoter
J. Biol. Chem., September 19, 2003; 278(38): 36496 - 36504.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Wm. K. Kelly, V. M. Richon, O. O'Connor, T. Curley, B. MacGregor-Curtelli, W. Tong, M. Klang, L. Schwartz, S. Richardson, E. Rosa, et al.
Phase I Clinical Trial of Histone Deacetylase Inhibitor: Suberoylanilide Hydroxamic Acid Administered Intravenously
Clin. Cancer Res., September 1, 2003; 9(10): 3578 - 3588.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. A. Plumb, P. W. Finn, R. J. Williams, M. J. Bandara, M. R. Romero, C. J. Watkins, N. B. La Thangue, and R. Brown
Pharmacodynamic Response and Inhibition of Growth of Human Tumor Xenografts by the Novel Histone Deacetylase Inhibitor PXD101
Mol. Cancer Ther., August 1, 2003; 2(8): 721 - 728.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. L. Antos, T. A. McKinsey, M. Dreitz, L. M. Hollingsworth, C.-L. Zhang, K. Schreiber, H. Rindt, R. J. Gorczynski, and E. N. Olson
Dose-dependent Blockade to Cardiomyocyte Hypertrophy by Histone Deacetylase Inhibitors
J. Biol. Chem., August 1, 2003; 278(31): 28930 - 28937.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Mitsiades, C. S. Mitsiades, P. G. Richardson, C. McMullan, V. Poulaki, G. Fanourakis, R. Schlossman, D. Chauhan, N. C. Munshi, T. Hideshima, et al.
Molecular sequelae of histone deacetylase inhibition in human malignant B cells
Blood, May 15, 2003; 101(10): 4055 - 4062.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Nimmanapalli, L. Fuino, C. Stobaugh, V. Richon, and K. Bhalla
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells
Blood, April 15, 2003; 101(8): 3236 - 3239.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Henderson, M. Mizzau, G. Paroni, R. Maestro, C. Schneider, and C. Brancolini
Role of Caspases, Bid, and p53 in the Apoptotic Response Triggered by Histone Deacetylase Inhibitors Trichostatin-A (TSA) and Suberoylanilide Hydroxamic Acid (SAHA)
J. Biol. Chem., March 28, 2003; 278(14): 12579 - 12589.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. Hockly, V. M. Richon, B. Woodman, D. L. Smith, X. Zhou, E. Rosa, K. Sathasivam, S. Ghazi-Noori, A. Mahal, P. A. S. Lowden, et al.
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease
PNAS, February 18, 2003; 100(4): 2041 - 2046.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. B. Glaser, M. J. Staver, J. F. Waring, J. Stender, R. G. Ulrich, and S. K. Davidsen
Gene Expression Profiling of Multiple Histone Deacetylase (HDAC) Inhibitors: Defining a Common Gene Set Produced by HDAC Inhibition in T24 and MDA Carcinoma Cell Lines
Mol. Cancer Ther., February 1, 2003; 2(2): 151 - 163.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. M. Butler, X. Zhou, W.-S. Xu, H. I. Scher, R. A. Rifkind, P. A. Marks, and V. M. Richon
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin
PNAS, September 3, 2002; 99(18): 11700 - 11705.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
H. Kamitani, S. Taniura, K. Watanabe, M. Sakamoto, T. Watanabe, and T. Eling
Histone acetylation may suppress human glioma cell proliferation when p21WAF/Cip1 and gelsolin are induced
Neuro-oncol, April 1, 2002; 4(2): 95 - 101.
[Abstract] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
F. Leoni, A. Zaliani, G. Bertolini, G. Porro, P. Pagani, P. Pozzi, G. Dona, G. Fossati, S. Sozzani, T. Azam, et al.
The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines
PNAS, February 20, 2002; (2002) 52702999.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Komatsu, K.-y. Tomizaki, M. Tsukamoto, T. Kato, N. Nishino, S. Sato, T. Yamori, T. Tsuruo, R. Furumai, M. Yoshida, et al.
Cyclic Hydroxamic-acid-containing Peptide 31, a Potent Synthetic Histone Deacetylase Inhibitor with Antitumor Activity
Cancer Res., June 1, 2001; 61(11): 4459 - 4466.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. C. Coffey, M. C. Kutko, R. D. Glick, L. M. Butler, G. Heller, R. A. Rifkind, P. A. Marks, V. M. Richon, and M. P. La Quaglia
The Histone Deacetylase Inhibitor, CBHA, Inhibits Growth of Human Neuroblastoma Xenografts in Vivo, Alone and Synergistically with All-Trans Retinoic Acid
Cancer Res., May 1, 2001; 61(9): 3591 - 3594.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
P. A. Marks, R. A. Rifkind, V. M. Richon, and R. Breslow
Inhibitors of Histone Deacetylase Are Potentially Effective Anticancer Agents
Clin. Cancer Res., April 1, 2001; 7(4): 759 - 760.
[Full Text]

Home page
 Clin. Cancer Res.Home page
L. M. Butler, Y. Webb, D. B. Agus, B. Higgins, T. R. Tolentino, M. C. Kutko, M. P. LaQuaglia, M. Drobnjak, C. Cordon-Cardo, H. I. Scher, et al.
Inhibition of Transformed Cell Growth and Induction of Cellular Differentiation by Pyroxamide, an Inhibitor of Histone Deacetylase
Clin. Cancer Res., April 1, 2001; 7(4): 962 - 970.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. Mishra, D. R. Brown, I. M. Olorenshaw, and G. M. Kammer
Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells
PNAS, February 15, 2001; (2001) 51507098.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. Mishra, D. R. Brown, I. M. Olorenshaw, and G. M. Kammer
Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells
PNAS, February 27, 2001; 98(5): 2628 - 2633.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
F. Leoni, A. Zaliani, G. Bertolini, G. Porro, P. Pagani, P. Pozzi, G. Dona, G. Fossati, S. Sozzani, T. Azam, et al.
The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines
PNAS, March 5, 2002; 99(5): 2995 - 3000.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. A. Ruefli, M. J. Ausserlechner, D. Bernhard, V. R. Sutton, K. M. Tainton, R. Kofler, M. J. Smyth, and R. W. Johnstone
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species
PNAS, September 11, 2001; 98(19): 10833 - 10838.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.